After Earnings Beat, Wall Street Talks Johnson & Johnson Litigation Risk
Analysts Shrug Off Softness In Edwards Lifesciences' Heart Value Replacement System
An Abbott Labs Analyst's 5 Reasons To Own The Stock: 'Near-Perfect For This Environment'
Analysts View Johnson & Johnson's Organic Growth Guidance As Conservative
Jayson Bedford Recent News
Raymond James Expects Johnson & Johnson's Growth To Accelerate Into 2020
Sell-Side Issues Positive Prognosis For Abbott Following Mixed Q4 Results, Strong 2019 Outlook
Analysts Stand By Johnson & Johnson Despite Earnings Pullback
The 4 Tailwinds Driving Raymond James' Insulet Bull Case
Boston Scientific Is 'Riding The Wave Of Business Improvement'